Evidence map›Paper›PMID 31892725›Full record

ArticleScientific reports2019

Short- and medium-term impact of bariatric surgery on the activities of CYP2D6, CYP3A4, CYP2C9, and CYP1A2 in morbid obesity.

Jose Rodríguez-Morató, Albert Goday, Klaus Langohr, Mitona Pujadas, Ester Civit, Clara Pérez-Mañá, Esther Papaseit, Jose Manuel Ramon, David Benaiges, Olga Castañer and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Transforming Treatment: The Impact of Bariatric Surgery on Oral Drug Absorption.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026
    Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Apixaban plasma concentrations in patients with obesity.European journal of clinical pharmacology · 2024
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Jose Rodríguez-MoratóDepartment of Experimental and Health Sciences, Universitat Pompeu Fabra (CEXS-UPF), Dr. Aiguader 80, Barcelona, 08003, Spain.ORCID http://orcid.org/0000-0002-8133-9983
Albert GodaySpanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition (CIBEROBN), Instituto Salud Carlos III, 28029, Madrid, Spain.
Klaus LangohrIntegrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program. IMIM (Hospital del Mar Medical Research Institute), Dr. Aiguader 88, Barcelona, 08003, Spain.
Mitona PujadasIntegrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program. IMIM (Hospital del Mar Medical Research Institute), Dr. Aiguader 88, Barcelona, 08003, Spain.
Ester CivitIntegrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program. IMIM (Hospital del Mar Medical Research Institute), Dr. Aiguader 88, Barcelona, 08003, Spain.
Clara Pérez-MañáIntegrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program. IMIM (Hospital del Mar Medical Research Institute), Dr. Aiguader 88, Barcelona, 08003, Spain.
Esther PapaseitIntegrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program. IMIM (Hospital del Mar Medical Research Institute), Dr. Aiguader 88, Barcelona, 08003, Spain.
Jose Manuel RamonSection of Gastrointestinal Surgery, Hospital del Mar, Barcelona, Spain.
David BenaigesDepartment of Endocrinology and Nutrition, Hospital del Mar, Barcelona, Spain.
Olga CastañerSpanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition (CIBEROBN), Instituto Salud Carlos III, 28029, Madrid, Spain.
Magí FarréIntegrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program. IMIM (Hospital del Mar Medical Research Institute), Dr. Aiguader 88, Barcelona, 08003, Spain.
Rafael de la TorreDepartment of Experimental and Health Sciences, Universitat Pompeu Fabra (CEXS-UPF), Dr. Aiguader 80, Barcelona, 08003, Spain. rtorre@imim.es.ORCID http://orcid.org/0000-0002-6765-1866
Universitat Autònoma de Barcelona · ESHospital Del Mar · ESSpanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition · ESUniversitat Pompeu Fabra · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Morbid obesity and bariatric surgery induce anatomical, physiological and metabolic alterations that may alter the body's disposition of drugs. Current literature on this topic is limited and sometimes inconsistent. Cytochrome P450 (CYP) is a superfamily of enzymes that metabolize around 75% of all marketed drugs. The purpose of this study was to evaluate the impact of body mass index and bariatric surgery on CYP activities. Firstly, we evaluated the in vivo activity of 4 major CYP isoenzymes (CYP2D6, CYP3A4, CYP2C9, and CYP1A2) in normal weight, overweight, and morbidly obese individuals. Secondly, we assessed the short- (1 month) and medium-term (6 month) effects of the most commonly employed bariatric surgery techniques (laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass) on the activity of these enzymes. CYP3A4 activity was lower in morbidly obese individuals, compared to normal-weight controls. Interestingly, bariatric surgery normalized CYP3A4 activity. In comparison with normal-weight controls, morbidly obese individuals had higher CYP2D6 activity, which was only observed in individuals with two functional alleles for this isoenzyme. Neither body mass index nor surgery had significant effects on CYP2C9 and CYP1A2 activities. Overall, no relevant differences in CYP activities were found between surgical techniques. In conclusion, further studies should evaluate whether the observed alterations in CYP3A4 activity will require dose adjustments for CYP3A4 substrates especially in morbidly obese individuals before and after bariatric surgery.

Indexed as

Bariatric SurgeryAdultCytochrome P-450 CYP1A2Cytochrome P-450 CYP2C9Cytochrome P-450 CYP2D6Cytochrome P-450 CYP3AFemaleHumansMaleMiddle AgedObesity, MorbidTreatment OutcomeYoung AdultCytochrome P-450 CYP1A2Cytochrome P-450 CYP2C9Cytochrome P-450 CYP2D6Cytochrome P-450 CYP3A

Identifiers

PMID31892725
PMCPMC6938522
OpenAlexW2997154420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.